AC Immune S.A. (ACIU) vs BridgeBio Oncology Therapeutics Inc. (BBOT)
A side-by-side comparison of AC Immune S.A. and BridgeBio Oncology Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACIU
AC Immune S.A.
$2.71HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.60HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ACIU vs BBOT
growth of $100 · dividends reinvested · last 3yACIU +1.9% (+0.6%/yr)BBOT -64.7% (-29.3%/yr)ACIU compounded faster over this window
ACIU BBOT
ACIU vs BBOT: by the numbers
- •BBOT is the larger company ($288M vs $276M market cap).
- •Both run net losses; BBOT's is the smaller (0.00% vs -249.94% net margin).
Metrics side by side
Valuation
| Metric | ACIU | BBOT |
|---|---|---|
| P/S ratio | 12.71 | N/A |
| P/B ratio | 6.34 | 0.89 |
Profitability
| Metric | ACIU | BBOT |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -1927.32% | 0.00% |
| Net margin | -249.94% | 0.00% |
| ROE | -124.67% | -56.36% |
| ROIC | -89.43% | -61.10% |
Growth (annualized)
| Metric | ACIU | BBOT |
|---|---|---|
| Revenue CAGR (5Y) | -23.70% | N/A |
| Total return CAGR (5Y) | -16.03% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.